2016
DOI: 10.1039/c5ob01594d
|View full text |Cite
|
Sign up to set email alerts
|

Identification of noreremophilane-based inhibitors of angiogenesis using zebrafish assays

Abstract: Noreremophilanes are a rare class of cis-hydrindanes produced by genus Ligularia herbaceous plants which are known to exhibit interesting biological activities. We synthesized cis-hydrindanes based on a naturally occurring noreremophilane scaffold using a Diels-Alder/aldol sequence and screened them for multiple biological activities using high-content zebrafish embryonic development assays. We discovered a noreremophilane that has strong anti-angiogenic effects on the developing zebrafish embryos as well as o… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0

Year Published

2016
2016
2021
2021

Publication Types

Select...
6
1

Relationship

1
6

Authors

Journals

citations
Cited by 11 publications
(4 citation statements)
references
References 38 publications
0
4
0
Order By: Relevance
“…The model was first described in 2007 (Nicoli et al, 2007) and, since then, it has been used to further the knowledge of the mechanisms of tumour angiogenesis: identifying genes of interest, determining the cellular processes involved in tumour angiogenesis and elucidating the functions carried out by tumour blood vessels (Vlecken and Bagowski, 2009; Zhao et al, 2016, 2011b). The main strengths of this model are the ability to image tumour angiogenesis in vivo and the applicability for drug screening (Harfouche et al, 2009; Yang et al, 2014a,b; Muthukumarasamy et al, 2016; Zhao et al, 2011b, 2016). While this model has gained popularity, the exact mechanisms that underpin xenograft angiogenesis in zebrafish are still unclear.…”
Section: Discussionmentioning
confidence: 99%
“…The model was first described in 2007 (Nicoli et al, 2007) and, since then, it has been used to further the knowledge of the mechanisms of tumour angiogenesis: identifying genes of interest, determining the cellular processes involved in tumour angiogenesis and elucidating the functions carried out by tumour blood vessels (Vlecken and Bagowski, 2009; Zhao et al, 2016, 2011b). The main strengths of this model are the ability to image tumour angiogenesis in vivo and the applicability for drug screening (Harfouche et al, 2009; Yang et al, 2014a,b; Muthukumarasamy et al, 2016; Zhao et al, 2011b, 2016). While this model has gained popularity, the exact mechanisms that underpin xenograft angiogenesis in zebrafish are still unclear.…”
Section: Discussionmentioning
confidence: 99%
“…30 Synthesis of compounds 12−17 were described in a recently published paper. 32 All the compounds were fully characterized by IR, 1 H NMR, 13 C NMR, and HRMS. Compounds 8, 19, 21, and 23 contain ∼10% diastereomer which was difficult to separate and they were screened as such; the remaining compounds were >95% pure as single diastereomers (judged from NMR).…”
Section: ■ Results and Discussionmentioning
confidence: 99%
“… Similarly, synthesis of (±)-nardoaristolone B and its analogues with cyclopropyl ring fusion were prepared . Synthesis of compounds 12–17 were described in a recently published paper . All the compounds were fully characterized by IR, 1 H NMR, 13 C NMR, and HRMS.…”
Section: Resultsmentioning
confidence: 99%
“…To date, a large number of angiogenesis inhibitors have been discovered and developed, ranging from monoclonal antibodies, endogenous angiogenesis peptide inhibitors, to small molecule drugs ( Figure 4 ). In the past few years, many emerging small molecule inhibitors have been synthesized, covering phosphatidylinositol 3-kinase, benzoxazines targeting receptor tyrosine kinase, 6-(pyrimidine-r-acyloxy)-naphthalene-1-carboxamides, and indoline-2-one group and noreremophilane-based inhibitors, respectively ( Al-Rawi et al, 2015 ; Muthukumarasamy et al, 2016 ). The mentioned emerging series of compounds showed potential for treating solid tumors in pre-clinical experiments.…”
Section: The Application Of Small Molecule Targeted Compounds In Cancersmentioning
confidence: 99%